眼科疾病治療市場規模、佔有率、成長分析、按疾病適應症、按藥物類別、按地區 - 產業預測，2025-2032

2023年眼疾治療市場規模為335億美元，從2024年的355.4億美元成長到2032年的570.8億美元，預測期間（2025-2032年）複合年成長率為6.10%，預計將維持在。

在眼科疾病盛行率上升和視力保健需求增加的推動下，全球眼科保健市場可望顯著成長。美國國家眼科美國透露，視力相關疾病每年對美國經濟造成約 1,390 億美元的損失。各大製藥公司正在大力投資視網膜疾病的創新治療方法，預計更先進的治療方法將在不久的將來獲得核准。此外，亞洲市場上經濟高效的非處方眼藥的出現可能會增加全球收益。抗發炎藥物、抗感染藥、抗VEGF藥物和抗青光眼藥物佔據市場主導地位，其中抗發炎藥物在2019年佔27%的佔有率，預計在預測期內將保持主導地位。

目錄

介紹

• 研究目的
• 調查範圍
• 定義

調查方法

• 資訊採購
• 二手資料和主要資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 按細分市場的機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制因素和挑戰
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024年）
• PESTEL分析
• 總體經濟指標
• 價值鏈分析
• 價格分析

按藥物類別分類的眼科疾病治療市場規模

• 市場概況
• 消炎（藥）
• 抗感染
• 抗VEGF
• 青光眼預防
  • BETA受體阻斷劑
  • 前列腺素類似物
  • α腎上腺素促效劑
  • 碳酸酐酶抑制劑
  • 伴隨藥物
  • 其他
• 其他

眼疾治療市場規模：以劑型分類

• 市場概況
• 固體的
• 液體
• 半固體

眼科疾病治療市場規模：依疾病適應症分類

• 市場概況
• 青光眼
  • 開放性青光眼
  • 隅角閉鎖性青光眼
  • 其他
• 乾眼症
• 視網膜疾病
• 糖尿病黃斑部水腫（DME）
• 黃斑部病變（AMD）
• 糖尿病視網膜病變 (DR)
• 視網膜靜脈阻塞（RVO）
• 過敏及感染疾病
• 其他

眼疾治療市場規模：依通路分類

• 市場概況
• 醫院藥房
• 零售及網路藥局

眼疾治療市場規模

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東/非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東/非洲

競爭資訊

• 前5名企業對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024年）
• 主要企業簡介
  • 公司簡介
  • 產品系列分析
  • 按細分市場分類的佔有率分析
  • 收益與前一年同期比較（2022-2024）

主要企業簡介

• Novartis AG（Switzerland）
• Roche Holding AG（Switzerland）
• Regeneron Pharmaceuticals, Inc.（USA）
• Allergan（part of AbbVie）（USA）
• Bausch Health Companies Inc.（Canada）
• Pfizer Inc.（USA）
• Merck & Co., Inc.（USA）
• Santen Pharmaceutical Co., Ltd.（Japan）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Otsuka Pharmaceutical Co., Ltd.（Japan）
• Alcon Inc.（Switzerland）
• Aerie Pharmaceuticals, Inc.（USA）
• Omeros Corporation（USA）
• Kodiak Sciences Inc.（USA）
• EyePoint Pharmaceuticals, Inc.（USA）
• Johnson & Johnson（USA）
• Abbott Laboratories（USA）
• Carl Zeiss Meditec AG（Germany）
• Topcon Corporation（Japan）
• Hoya Corporation（Japan）

結論和建議

Ophthalmic Disease Therapeutics Market size was valued at USD 33.5 Billion in 2023 and is poised to grow from USD 35.54 Billion in 2024 to USD 57.08 Billion by 2032, growing at a CAGR of 6.10% during the forecast period (2025-2032).

The global market for ophthalmic therapeutics is set for significant growth, driven by the rising incidence of ocular diseases and an escalating demand for vision care. The National Eye Institute highlights that vision-related ailments cost the U.S. economy approximately $139 billion annually. Major pharmaceutical firms are heavily investing in innovative therapies for retinal disorders, with more advanced treatments expected to gain approval in the near future. Additionally, the advent of cost-effective over-the-counter ophthalmic drugs in Asian markets is likely to boost global revenues. Anti-inflammatory, anti-infectives, anti-VEGF, and anti-glaucoma treatments dominate the market, with anti-inflammatory drugs capturing a substantial 27% share in 2019 and expected to maintain a leading position throughout the forecast period.

Top-down and bottom-up approaches were used to estimate and validate the size of the Ophthalmic Disease Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Ophthalmic Disease Therapeutics Market Segmental Analysis

Global Ophthalmic Disease Therapeutics Market is segmented by Drug Class, Dosage Form, Disease Indication, Distribution Channel and region. Based on Drug Class, the market is segmented into anti-inflammatory, anti-infectives, Anti-VEGF, anti-glaucoma and others. Based on Dosage Form, the market is segmented into solid, liquid and semisolid. Based on Disease Indication, the market is segmented into glaucoma, dry eye disease, retinal diseases, allergy & infections and others. Based on Distribution Channel, the market is segmented into hospital pharmacies and retail & online pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Ophthalmic Disease Therapeutics Market

The growth of the ophthalmic disease therapeutics market is significantly driven by the increasing presence of small and mid-sized companies that are diversifying the competitive landscape. Key industry players, including Allergan plc, F. Hoffmann-La Roche AG, and Regeneron Pharmaceuticals, Inc., compete alongside these smaller entities, leading to a fragmented market. This competition fosters innovation and the development of new treatment options for prevalent ophthalmic conditions such as macular degeneration, macular edema, and retinal vein occlusion. Established treatments like Eylea from Regeneron and Lucentis from F. Hoffmann-La Roche continue to play pivotal roles in effectively managing these diseases, further stimulating market expansion.

Restraints in the Ophthalmic Disease Therapeutics Market

The Ophthalmic Disease Therapeutics market faces significant constraints primarily due to the extended timelines required for the manufacturing and formulation of ophthalmic medications. Additionally, the potential side effects associated with these drugs pose another challenge that could hinder market expansion during the forecast period. The complexity of developing these treatments, coupled with the need for thorough testing and regulatory approvals, often results in delays that may deter investment and innovation in this sector. Consequently, these factors are anticipated to limit the overall growth potential of the ophthalmic therapeutics market in the foreseeable future.

Market Trends of the Ophthalmic Disease Therapeutics Market

The Ophthalmic Disease Therapeutics market is witnessing a robust trend driven by rapid technological advancements in ophthalmology, particularly in imaging techniques and surgical tools that enhance patient outcomes. Innovations such as femtosecond lasers in cataract surgery exemplify the shift towards more precise and safer procedures, minimizing complications and improving recovery times. Additionally, the integration of artificial intelligence in diagnostic tools is streamlining patient assessments, allowing for earlier detection and personalized treatment approaches. As a result, these developments are attracting investment and market interest, thereby fostering growth and significantly enhancing the overall landscape of ophthalmic disease management.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Ophthalmic Disease Therapeutics Market Size by Drug Class & CAGR (2025-2032)

• Market Overview
• Anti-Inflammatory
• Anti-Infectives
• Anti-VEGF
• Anti-Glaucoma
  • Beta Blockers
  • Prostaglandins Analogs
  • Alpha Adrenergic Agonists
  • Carbonic Anhydrase Inhibitors
  • Combination Drugs
  • Others
• Others

Global Ophthalmic Disease Therapeutics Market Size by Dosage Form & CAGR (2025-2032)

• Market Overview
• Solid
• Liquid
• Semisolid

Global Ophthalmic Disease Therapeutics Market Size by Disease Indication & CAGR (2025-2032)

• Market Overview
• Glaucoma
  • Open Angle Glaucoma
  • Angle Closure Glaucoma
  • Others
• Dry Eye Disease
• Retinal Diseases
• Diabetic Macular Edema (DME)
• Macular Degeneration (AMD)
• Diabetic Retinopathy (DR)
• Retinal Vein Occlusion (RVO)
• Allergy & Infections
• Others

Global Ophthalmic Disease Therapeutics Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacies
• Retail & Online Pharmacies

Global Ophthalmic Disease Therapeutics Market Size & CAGR (2025-2032)

• North America (Drug Class, Dosage Form, Disease Indication, Distribution Channel)
  • US
  • Canada
• Europe (Drug Class, Dosage Form, Disease Indication, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Class, Dosage Form, Disease Indication, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Class, Dosage Form, Disease Indication, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Class, Dosage Form, Disease Indication, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Allergan (part of AbbVie) (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bausch Health Companies Inc. (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Santen Pharmaceutical Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Otsuka Pharmaceutical Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alcon Inc. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aerie Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Omeros Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kodiak Sciences Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• EyePoint Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Carl Zeiss Meditec AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Topcon Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hoya Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations